The PCOS Name Change: What It Means, Why It Matters, and What Still Needs to Change

Coach Cate talks about the importance of renaming PCOS to PMOS (Polyendocrine Metabolic Ovarian Syndrome). She talks about what this means for women's medicine, what work is still left to be done, and how this is (hopefully) going to change how PMOS is treated in conventional medicine. Functional Medicine has been saying PCOS is a metabolic condition for years - and conventional medicine is finally catching up! 

Transcript

SPEAKER_00 0:00

Hey, hey, welcome back to Healthy Period. I'm Coach Kate, and I need to talk about what happened yesterday. Because if you haven't heard, PCOS got a new name. And I know what some of you have been thinking, it's just a name change, does it actually matter? But I want to spend this entire episode answering that question because yes, it matters. It matters more than most people realize. And it also doesn't go far enough. And we need to talk about that too. So for the women who have been dismissed, misdiagnosed, undertreated, and told their symptoms were just stress or just wait, this moment is for you. This is not just a semantic change. This is medicine slowly, finally, beginning to catch up with what women's bodies have been telling us for decades. So let's just jump right in. Let's start with the facts. PCOS, polycystic ovarian syndrome, has officially been renamed to PMOS, polyendocrine metabolic ovarian syndrome. And I want to break down every single word of that new name because each one tells you something important. So polyendocrine. The original name, polycystic, focused on the ovaries, specifically the appearance of multiple follicles on an ultrasound. But here's the problem with that. As we talked about in our PCOS episodes, you don't even need polycystic ovaries to have PCOS. The cysts aren't even really cysts, they're immature follicles. And the name polycystic has caused decades of confusion. Women without ovarian cysts being told they can't have PCOS, women with cysts being told they definitely have PCOS, doctors focusing on the ovaries as the origin point, where the ovaries are often responding to a much bigger systemic issue. Polyendocrine tells a completely different story. Endocrine refers to the hormonal system, the entire network of glands and hormones that regulate your metabolism, reproduction, stress response, thyroid function, insulin signaling, and adrenal function. So polyendocrine means multiple endocrine systems are involved. This is the truth that functional practitioners have been saying for years. PCOS, now PMOS, is not an ovarian condition. It is a systemic, hormonal, and metabolic condition that affects the ovaries, but it is driven by much broader dysfunction. That is just so huge. And metabolic, this is the word that I want to spend the most time on because this is the word that changes everything for treatment, which, if you are a client of mine, you know this is where we go deep. If you come to me with a PCOS diagnosis already, metabolic acknowledges what the research has been showing. PCOS, PMOS, is fundamentally a metabolic condition. It involves insulin resistance, blood sugar dysregulation, inflammation, lipid metabolism, cardiovascular risk, body composition changes, mitochondrial function. This is why women with PCOS struggle with weight in ways that don't respond to conventional advice, have blood sugar instability, have elevated androgen levels, driven by insulin, have increased cardiovascular risk, and have an increased risk of type 2 diabetes. So for decades, the metabolic component of PCOS was either dismissed entirely, addressed with only lose weight, treated as a consequence of PCOS rather than a driver of it. The word metabolic in the new name says this is a metabolic condition first. The ovarian symptoms are downstream, and treatment must address metabolism, not just suppress the symptoms. That's a huge fundamental shift in how this condition is framed. And framing is going to drive our treatment. So the word ovarian, the ovaries are still in the name because the ovaries are still involved, but now they're positioned correctly as one part of a much larger systemic picture. It's not the origin, it's not the problem, but one of the organs affected by a broader endocrine and metabolic dysfunction. And syndrome remains. And I think that's worth acknowledging what that means. A syndrome is a collection of signs and symptoms that tend to occur together, but they don't have a single clearly defined cause. This is both, this is both honest and limiting. Honest because PMOS genuinely presents differently in different women. It's limiting because syndrome still doesn't point us towards a specific mechanism or a clear treatment pathway. And this is part of the conversation that we still need to have. And I want to just take a moment and step away from the science because I could nerd out on you guys all day long. But I want to talk about what this means for real women, because behind every diagnostic label is a human being. And the women who have been living with this condition under the old name and the old framework have been failed in very specific ways. So here's what the PCOS experience has looked like for most women. And if you're listening to this, you probably have experienced this. You go to your doctor with irregular cycles, weight gain you can't explain, acne, hair thinning, fatigue, mood changes, difficulty losing weight despite trying. And then you're told you have to lose weight, go on the pill, your labs are normal. This is just how your body is, or come back when you want to get pregnant. The old name, PCOS, framed this as an ovarian problem. And ovarian problems in conventional medicine are managed with hormonal suppression, fertility interventions, and weight loss advice. The metabolic drivers are ignored, the endocrine complexity is ignored, and women's lived experiences are ignored. But what the new name says for these women, polyendocrine metabolic ovarian syndrome, it says that this is real, this is systemic, this is metabolic, it's not just about your ovaries, it's not just about your weight, and it's not just in your head. For a woman who has spent years being dismissed, this validation isn't small. It's everything. Because when medicine changes its language, it changes what it looks for. And when it changes what it looks for, it changes what it finds. And when it changes what it finds, it changes how it's treated. I also want to acknowledge something that is painful, but very true. That this name change comes after decades of women being misdiagnosed, being undertreated, developing type 2 diabetes that could have been prevented, developing cardiovascular disease that could have been caught earlier, struggling with infertility that could have been addressed differently, and living with symptoms that are manageable but were never managed. The name change is a step forward, but it does not erase the years women spent in a system that didn't have the right framework to help them. And I think that's important to hold both things true at once, that this is progress, but it also came too late for many women. But I want to talk about the future of treatment because this is where I get excited, because a name change in medicine is not just symbolic. The name drives research funding, diagnostic criteria, treatment protocols, insurance coverage, pharmaceutical development, and medical education. So when PCOS was framed as an ovarian condition, the research followed the ovaries. Treatment focused on the ovaries, and education was focused on the ovaries. But when PMOS is framed as a polyendocrine metabolic condition, everything's gonna shift. Now, what should we start seeing in treatment? Number one, metabolic assessment becomes the standard. So instead of just looking at ovarian morphology and androgen levels, practitioners should now be looking at insulin-resistant markers, inflammatory markers, lipid panels, thyroid function, adrenal function, gut health indicators, and nutrient status. Number two, insulin-sensitizing interventions become first line. So rather than defaulting to the pill, metabolic interventions should be first up. Dietary approaches that support insulin sensitivity, movement protocols designed for metabolic health, targeted supplementation, lifestyle interventions with real clinical support. And cardiovascular risk should be taken seriously earlier. So women with PMOS have elevated cardiovascular risk, and that risk begins accumulating long before menopause. The new framing should prompt earlier cardiovascular screening, lipid management that goes beyond losing weight, blood pressure monitoring, and inflammation assessment. And we should see a mental health integration. The psychological burden of PMOS is significant. Anxiety, depression, disordered eating, body image, fertility grief, these are not separate issues. They're part of the condition and they deserve to be treated as such. And hopefully the fertility conversations change. When the metabolic drivers are addressed, ovulation can return. Fertility support for women with PMOS should include metabolic optimization before jumping to IVF, insulin sensitization, inflammation reduction, hormonal environment support. This does not mean that IVF is never appropriate. It just means it shouldn't be the first conversation. So from a functional nutritional therapy lens, this name change validates everything that we've already been doing. We have always looked at insulin and blood sugar, inflammation, gut health, adrenal function, thyroid, nutrient status, and stress physiology. We have always said the ovaries are responding, not originating. The new name is just going to say the same thing. And while conventional medicine is just now arriving at this framing, functional practitioners have been here for years. And that's why the work that we do matters. And I want to be honest about something because the name change is meaningful, but the diagnostic criteria, that conversation is still very much unresolved. Currently, the Rotterdam criteria remains the most widely used diagnostic framework. So two out of the three, irregular or absent ovulation, hyperandrogym, and polycystic ovarian morphology on an ultrasound. And while the name is changing, the criteria have not yet been formally updated to reflect the new metabolic framing. This is a huge gap because you can meet the Rotterdam criteria without ever having insulin resistance assessed, without ever looking at inflammatory markers, without ever having a full thyroid panel run, without ever having androgen, adrenal androgens evaluated. So the debate and the research, it's active, it's ongoing, and it does take a long time for the medical community to get up to speed. So should insulin resistance be a diagnostic criteria? Given that insulin resistance is present in 70% of women with PMOS and it's considered a primary driver of the condition, many researchers argue that it should be formally included. But there is a counter argument that not all women with PMOS have measurable insulin resistance by standard markers. There are some limitations with the diagnostic tool, and there's no universal agreement on the cutoffs. Should the ultrasound criteria be removed or revised, ultrasound technology has changed dramatically, and what was once considered polycystic on older machines may look different now on new equipment. So some researcher, some researchers are arguing that ultrasound criteria creates more confusion than clarity. And also, given that there are four distinct phenotypes, some researchers argue that single diagnostic framework can't adequately capture the diversity of the PMOS presentations. So we want more specific criteria for more targeted treatment, for better research outcomes, and more accurate prevalence data. But should metabolic markers be standardized? There's no current consensus on that. They don't know which metabolic markers should be assessed, what cutoff defines metabolic dysfunction in PMOS, or how to account for weight-independent insulin resistance. So here's the practical reality: a woman can go to her doctor today after the name change and still be diagnosed or dismissed using the same diagnostic criteria that's been in place since 2003. The name has changed, but the framework has not yet. And until the diagnostic criteria catch up with a new understanding of PMOS, women are going to continue to fall through the cracks. Women who have insulin resistance without classic PMOS features, metabolic dysfunction without irregular cycles, adrenal androgen excess without ovarian cysts. You'll be continued to be missed. The name change is a step forward, but the work is not done. So what do I want you to take away from all of this? Number one, your symptoms were always real. The name change does not make your experience more valid. It was always valid, but now medicine is slowly building a framework that reflects what you've already been living. Number two, you do not have to wait for medicine to catch up. The functional approach, looking at insulin, inflammation, gut health, adrenals, thyroid, nutrients, it's always been the right approach. You can pursue root cause support right now, regardless of what your diagnosis is called. Number three, ask better questions at your appointments. Now that the metabolic framing is becoming mainstream, you can ask, can we assess my insulin resistance? Can we run a fasted insulin? Can we look at my inflammatory markers? Can we do a full thyroid panel? What metabolic interventions are appropriate for me? And number four, I want you to share this episode because there are so many women in your life, your sisters, your friends, your daughters, who have been dismissed with this diagnosis for years, and they deserve to know that medicine is finally starting to acknowledge them. Yesterday was such a meaningful day for women's health. The renaming of PCOS to PMOS represents a shift in how medicine understands, and we also hope how medicine treats this condition. It validates what functional practitioners have been saying for years, it validates what women have been experiencing for decades, and it opens a door to better research, better treatment, and better outcomes. But I want to be very clear a name change is the beginning, it's not the end. The diagnostic criteria need to evolve, the treatment protocols need to change, the dismissal of women's symptoms needs to stop, and the metabolic drivers need to be addressed, not suppressed. And until that happens, I want to keep talking about it. I want to keep educating. We need to keep advocating for ourselves, for each other, for the women who come after us. And if this episode was everything you've ever wanted, I really want you to share it with every woman you know has been living with this diagnosis. And if you do want to go deeper, I am going to be hosting another PCOS, PMOS masterclass in a few weeks. We're going to cover everything we talked about today and so much more. So DM me on Instagram masterclass to get on the wait list, and I'll send you the link to register as soon as it's live. So thanks for listening to Healthy Period. I'll see you on the next episode.